Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Saturday.
A number of other brokerages have also commented on NAGE. Canaccord Genuity Group boosted their price target on Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday. Roth Capital reiterated a "buy" rating and set a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th.
Read Our Latest Report on Niagen Bioscience
Niagen Bioscience Price Performance
Shares of Niagen Bioscience stock opened at $13.63 on Friday. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of 80.18 and a beta of 2.08. The stock's 50-day moving average is $9.25 and its 200-day moving average is $7.12. Niagen Bioscience has a one year low of $2.31 and a one year high of $14.49.
Niagen Bioscience Company Profile
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
